We combine this unique stress ligand-targeting approach with NK cells and take advantage of the extensive high expression of MICB in solid tumors to design a targeted anti-tumor CAR-NK drug that will provide more anti-tumor properties than conventional NK cells, including broad solid tumor responsiveness. The gene discussed is MICB; the disease is neoplasm.